CN114430681A - 使用egfr和cdk4/6抑制剂的组合治疗egfr突变相关的癌症 - Google Patents

使用egfr和cdk4/6抑制剂的组合治疗egfr突变相关的癌症 Download PDF

Info

Publication number
CN114430681A
CN114430681A CN202080066624.7A CN202080066624A CN114430681A CN 114430681 A CN114430681 A CN 114430681A CN 202080066624 A CN202080066624 A CN 202080066624A CN 114430681 A CN114430681 A CN 114430681A
Authority
CN
China
Prior art keywords
formula
cancer
egfr
hydrogen
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080066624.7A
Other languages
English (en)
Chinese (zh)
Inventor
迈克尔·尼古拉斯·格雷科
迈克尔·约翰·科斯坦佐
迈克尔·艾伦·格林
张顿
彭继荣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beta Pharma Inc
Original Assignee
Beta Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beta Pharma Inc filed Critical Beta Pharma Inc
Publication of CN114430681A publication Critical patent/CN114430681A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080066624.7A 2019-09-23 2020-09-23 使用egfr和cdk4/6抑制剂的组合治疗egfr突变相关的癌症 Pending CN114430681A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962904567P 2019-09-23 2019-09-23
US62/904,567 2019-09-23
PCT/US2020/052096 WO2021061695A1 (en) 2019-09-23 2020-09-23 Treatment of egfr mutant-related cancers using a combination of egfr and cdk4/6 inhibitors

Publications (1)

Publication Number Publication Date
CN114430681A true CN114430681A (zh) 2022-05-03

Family

ID=75166417

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080066624.7A Pending CN114430681A (zh) 2019-09-23 2020-09-23 使用egfr和cdk4/6抑制剂的组合治疗egfr突变相关的癌症

Country Status (7)

Country Link
US (1) US12390464B2 (https=)
EP (1) EP4034121A4 (https=)
JP (1) JP2022549272A (https=)
CN (1) CN114430681A (https=)
AU (1) AU2020352528A1 (https=)
TW (1) TW202126305A (https=)
WO (1) WO2021061695A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220079944A1 (en) * 2019-01-29 2022-03-17 Beta Pharma, Inc. 2h-indazole derivatives as therapeutic agents for brain cancers and brain metastases

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105085489A (zh) * 2014-11-05 2015-11-25 上海页岩科技有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
CN106687454A (zh) * 2014-07-24 2017-05-17 贝达医药公司 作为细胞周期蛋白依赖性激酶(cdk)抑制剂的2h‑吲唑衍生物及其医疗用途
CN108024993A (zh) * 2014-12-11 2018-05-11 贝达医药公司 取代的2-苯胺基嘧啶衍生物及其作为表皮生长因子受体调节剂
WO2018091999A1 (en) * 2016-11-16 2018-05-24 Pfizer Inc. Combination of an egfr t790m inhibitor and a cdk inhibitor for the treatment of non-small cell lung cancer
WO2018156812A1 (en) * 2017-02-22 2018-08-30 G1 Therapeutics, Inc. Treatment of egfr-driven cancer with fewer side effects

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106687454A (zh) * 2014-07-24 2017-05-17 贝达医药公司 作为细胞周期蛋白依赖性激酶(cdk)抑制剂的2h‑吲唑衍生物及其医疗用途
CN105085489A (zh) * 2014-11-05 2015-11-25 上海页岩科技有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
CN108024993A (zh) * 2014-12-11 2018-05-11 贝达医药公司 取代的2-苯胺基嘧啶衍生物及其作为表皮生长因子受体调节剂
WO2018091999A1 (en) * 2016-11-16 2018-05-24 Pfizer Inc. Combination of an egfr t790m inhibitor and a cdk inhibitor for the treatment of non-small cell lung cancer
WO2018156812A1 (en) * 2017-02-22 2018-08-30 G1 Therapeutics, Inc. Treatment of egfr-driven cancer with fewer side effects

Also Published As

Publication number Publication date
US12390464B2 (en) 2025-08-19
WO2021061695A1 (en) 2021-04-01
TW202126305A (zh) 2021-07-16
US20220347177A1 (en) 2022-11-03
JP2022549272A (ja) 2022-11-24
AU2020352528A1 (en) 2022-04-21
EP4034121A4 (en) 2023-10-18
EP4034121A1 (en) 2022-08-03

Similar Documents

Publication Publication Date Title
US20240299388A1 (en) Erk1/2 and shp2 inhibitors combination therapy
TWI808958B (zh) 涉及二芳基巨環化合物之組合療法
TW202529768A (zh) 癌症治療的療法
RU2660354C2 (ru) Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение
CN115768423A (zh) Egfr、kras、braf和其他靶标的抑制剂及其用途
CN105120868A (zh) 组合治疗
CN115397413A (zh) Egfr、kras、braf和其他靶标的抑制剂及其用途
JP2017214387A (ja) 増殖性疾患の治療のためのｈｓｐ９０阻害剤と組み合わせた２−カルボキサミドシクロアミノウレア誘導体
TW202133856A (zh) 涉及二芳基巨環化合物之組合療法
JP7670711B2 (ja) ジアリール大環状化合物を含む併用療法
JP2011513364A (ja) Ｅｇｆｒ依存性疾患またはｅｇｆｒファミリーメンバーを標的とする薬剤に対して耐性を獲得した疾患を治療するためのピリミジン誘導体の使用
TW201822769A (zh) 用於治療非小細胞肺癌之egfr t790m 抑制劑及cdk抑制劑之組合
JP2024537136A (ja) ＫＲＡＳ Ｇ１２Ｄ阻害剤と汎ＥｒｂＢファミリー阻害剤との併用療法
CN105338980A (zh) 药物组合
JP2020114849A (ja) Ｅｇｆｒ依存性疾患またはｅｇｆｒファミリーメンバーを標的とする薬剤に対して獲得耐性を有する疾患の治療における２−カルボキサミドシクロアミノウレア誘導体の使用
JP2021525244A (ja) 腫瘍性疾患を治療するための薬剤の調製におけるｅｇｆｒ阻害剤と組み合わせたｃｄｋ４／６阻害剤の使用
CN116261455A (zh) 一种药物组合物及其在治疗癌症中的用途
CN114430681A (zh) 使用egfr和cdk4/6抑制剂的组合治疗egfr突变相关的癌症
WO2025157287A1 (zh) 包含prmt5抑制剂和egfr抑制剂的药物组合物
TWI623315B (zh) ３－［（３－｛［４－（４－嗎啉基甲基）－１ｈ－吡咯－２－基］亞甲基｝－２－側氧基－２，３－二氫－１ｈ－吲哚－５－基）甲基］－１，３－噻唑啶－２，４－二酮及ｅｇｆｒ ｔｙｒ激酶抑制劑之新穎結合物
RU2784853C2 (ru) Комбинационная терапия с применением диарильных макроциклических соединений
CN121013721A (zh) 包含kras抑制剂和sph2抑制剂的组合疗法
HK40109894A (zh) Kras g12d抑制剂与泛erbb家族抑制剂的组合疗法
CN121398849A (zh) 包含prmt5抑制剂和pd-1/pd-l1抑制剂的药物组合物
WO2012026511A1 (ja) 医薬組成物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination